Search results
Results from the WOW.Com Content Network
The Quality of drugs and Active Pharmaceutical Ingredients (API) made by Chinese pharmaceutical companies is often poor. In the past three years 2015–2017, there were 35 FDA warning letters to Chinese pharmaceutical companies citing serious Data Integrity issues, including data deletion or manipulation or fabrication of test results, see "An Analysis of 2017 FDA Warning Letters on Data ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Pharmaceutical companies of China (2 C, 37 P) ... Pharmaceutical companies of the United States (16 C, 212 P) V. Pharmaceutical companies of Vietnam (1 P)
The Chinese government has designated biotechnology (and drug manufacturing) as a top priority industry for its “Made in China 2025” initiative. The United States must respond in kind by ...
*Note: this list includes joint-ventures based in Michigan, subsidiaries of Michigan-based companies also located in Michigan, and companies based in Michigan currently owned or controlled by private equity, venture capital, or other similar entities. Below is a separate list of outside companies with a significant presence in Michigan.
Pages in category "Pharmaceutical companies of China" The following 37 pages are in this category, out of 37 total. This list may not reflect recent changes. B.
China Medical System will be responsible for the regulatory, development, manufacturing, and commercialization of Zunveyl in the licensed territories. Alpha Cognition remains on track to launch ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.